HEADER TRANSFERASE/TRANSFERASE INHIBITOR 08-JAN-16 5HG8 TITLE EGFR (L858R, T790M, V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- TITLE 2 PYRAZOL-4-YL)AMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- TITLE 3 2-ENAMIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: EPIDERMAL GROWTH FACTOR RECEPTOR; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: UNP RESIDUES 695-1022; COMPND 5 SYNONYM: PROTO-ONCOGENE C-ERBB-1,RECEPTOR TYROSINE-PROTEIN KINASE COMPND 6 ERBB-1; COMPND 7 EC: 2.7.10.1; COMPND 8 ENGINEERED: YES; COMPND 9 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: EGFR, ERBB, ERBB1, HER1; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108 KEYWDS EGFR, KINASE, INHIBITOR, LUNG CANCER, TRANSFERASE-TRANSFERASE KEYWDS 2 INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR K.S.GAJIWALA REVDAT 5 06-MAR-24 5HG8 1 REMARK REVDAT 4 22-NOV-17 5HG8 1 JRNL REMARK REVDAT 3 23-MAR-16 5HG8 1 JRNL REVDAT 2 10-FEB-16 5HG8 1 JRNL REVDAT 1 03-FEB-16 5HG8 0 JRNL AUTH H.CHENG,S.K.NAIR,B.W.MURRAY,C.ALMADEN,S.BAILEY,S.BAXI, JRNL AUTH 2 D.BEHENNA,S.CHO-SCHULTZ,D.DALVIE,D.M.DINH,M.P.EDWARDS, JRNL AUTH 3 J.L.FENG,R.A.FERRE,K.S.GAJIWALA,M.D.HEMKENS, JRNL AUTH 4 A.JACKSON-FISHER,M.JALAIE,T.O.JOHNSON,R.S.KANIA,S.KEPHART, JRNL AUTH 5 J.LAFONTAINE,B.LUNNEY,K.K.LIU,Z.LIU,J.MATTHEWS,A.NAGATA, JRNL AUTH 6 S.NIESSEN,M.A.ORNELAS,S.T.ORR,M.PAIRISH,S.PLANKEN,S.REN, JRNL AUTH 7 D.RICHTER,K.RYAN,N.SACH,H.SHEN,T.SMEAL,J.SOLOWIEJ,S.SUTTON, JRNL AUTH 8 K.TRAN,E.TSENG,W.VERNIER,M.WALLS,S.WANG,S.L.WEINRICH,S.XIN, JRNL AUTH 9 H.XU,M.J.YIN,M.ZIENTEK,R.ZHOU,J.C.KATH JRNL TITL DISCOVERY OF JRNL TITL 2 1-{(3R,4R)-3-[({5-CHLORO-2-[(1-METHYL-1H-PYRAZOL-4-YL) JRNL TITL 3 AMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL}OXY) JRNL TITL 4 METHYL]-4-METHOXYPYRROLIDIN-1-YL}PROP-2-EN-1-ONE JRNL TITL 5 (PF-06459988), A POTENT, WT SPARING, IRREVERSIBLE INHIBITOR JRNL TITL 6 OF T790M-CONTAINING EGFR MUTANTS. JRNL REF J.MED.CHEM. V. 59 2005 2016 JRNL REFN ISSN 0022-2623 JRNL PMID 26756222 JRNL DOI 10.1021/ACS.JMEDCHEM.5B01633 REMARK 2 REMARK 2 RESOLUTION. 1.42 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2005 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.42 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 58.99 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 1173784.010 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 98.9 REMARK 3 NUMBER OF REFLECTIONS : 58555 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.208 REMARK 3 R VALUE (WORKING SET) : 0.208 REMARK 3 FREE R VALUE : 0.213 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.700 REMARK 3 FREE R VALUE TEST SET COUNT : 2761 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.004 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.2100 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.2100 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.213 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 4.700 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 2773 REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : 0.0040 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 58858 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.42 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.51 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 93.80 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 8710 REMARK 3 BIN R VALUE (WORKING SET) : 0.2940 REMARK 3 BIN FREE R VALUE : 0.2930 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.20 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 385 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.015 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2418 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 44 REMARK 3 SOLVENT ATOMS : 209 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 18.00 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 21.20 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 8.43000 REMARK 3 B22 (A**2) : -3.34000 REMARK 3 B33 (A**2) : -5.10000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.17 REMARK 3 ESD FROM SIGMAA (A) : 0.17 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.18 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.15 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.004 REMARK 3 BOND ANGLES (DEGREES) : 0.800 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 18.80 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.640 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.150 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 1.780 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.070 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.030 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.38 REMARK 3 BSOL : 39.35 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP-EDITED.PARAM REMARK 3 PARAMETER FILE 2 : ACCELRYS_CNX:LIBRARIES/TOPPAR/DNA REMARK 3 -RNA_REP.PARA REMARK 3 PARAMETER FILE 3 : REMARK 3 ACCELRYS_CNX:LIBRARIES/TOPPAR/WATER_REP.PARAM REMARK 3 PARAMETER FILE 4 : ACCELRYS_CNX:LIBRARIES/TOPPAR/ION.PARAM REMARK 3 PARAMETER FILE 5 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN-EDITED.TOP REMARK 3 TOPOLOGY FILE 2 : ACCELRYS_CNX:LIBRARIES/TOPPAR/DNA-RNA.TOP REMARK 3 TOPOLOGY FILE 3 : ACCELRYS_CNX:LIBRARIES/TOPPAR/WATER.TOP REMARK 3 TOPOLOGY FILE 4 : ACCELRYS_CNX:LIBRARIES/TOPPAR/ION.TOP REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5HG8 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 19-JAN-16. REMARK 100 THE DEPOSITION ID IS D_1000216988. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 19-APR-12 REMARK 200 TEMPERATURE (KELVIN) : 98 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : SCALA, AUTOPROC REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 58632 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.420 REMARK 200 RESOLUTION RANGE LOW (A) : 58.990 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 200 DATA REDUNDANCY : 6.300 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.06400 REMARK 200 FOR THE DATA SET : 15.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.42 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.50 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 6.40 REMARK 200 R MERGE FOR SHELL (I) : 0.49000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.900 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 39.97 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.05 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1 M (5.0 UL OF STOCK 1.0 M) HEPES REMARK 280 (PH 7.50), 0.2 M (2.8571428571 UL OF STOCK 3.5 M) AMMONIUM REMARK 280 SULFATE, 20.0 %W/V (20.0 UL OF STOCK 50.0 %W/V) PEG 8000, 10.0 % REMARK 280 V/V (5.0 UL OF STOCK 100.0 %V/V) ISO-PROPANOL, VAPOR DIFFUSION, REMARK 280 SITTING DROP, TEMPERATURE 286K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 19.96600 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 55.30500 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 34.86500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 55.30500 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 19.96600 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 34.86500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 694 REMARK 465 SER A 695 REMARK 465 GLY A 696 REMARK 465 GLU A 697 REMARK 465 ALA A 698 REMARK 465 PRO A 699 REMARK 465 ALA A 1000 REMARK 465 LEU A 1001 REMARK 465 MET A 1002 REMARK 465 ASP A 1003 REMARK 465 GLU A 1004 REMARK 465 GLU A 1005 REMARK 465 ASP A 1006 REMARK 465 MET A 1007 REMARK 465 ASP A 1008 REMARK 465 ASP A 1009 REMARK 465 VAL A 1010 REMARK 465 VAL A 1011 REMARK 465 ASP A 1012 REMARK 465 ALA A 1013 REMARK 465 ASP A 1014 REMARK 465 GLU A 1015 REMARK 465 TYR A 1016 REMARK 465 LEU A 1017 REMARK 465 ILE A 1018 REMARK 465 PRO A 1019 REMARK 465 GLN A 1020 REMARK 465 GLN A 1021 REMARK 465 GLY A 1022 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 783 -124.38 -130.92 REMARK 500 ASP A 837 38.32 -149.23 REMARK 500 GLU A 872 -165.45 -105.40 REMARK 500 REMARK 500 REMARK: NULL REMARK 600 REMARK 600 HETEROGEN REMARK 600 REMARK 600 THE 634 LIGAND REPRESENT BOUND FORM OF N-[3-({2-[(1-METHYL-1H- REMARK 600 PYRAZOL-4-YL)AMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- REMARK 600 2-ENAMIDE WHICH HAS A DOUBLE BOND BETWEEN C20 AND C21 ATOM GROUP. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 634 A 9001 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue SO4 A 9002 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue SO4 A 9003 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue GOL A 9004 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 5HG7 RELATED DB: PDB REMARK 900 RELATED ID: 5HG5 RELATED DB: PDB REMARK 900 RELATED ID: 5HG9 RELATED DB: PDB DBREF 5HG8 A 695 1022 UNP P00533 EGFR_HUMAN 695 1022 SEQADV 5HG8 GLY A 694 UNP P00533 EXPRESSION TAG SEQADV 5HG8 MET A 790 UNP P00533 THR 790 ENGINEERED MUTATION SEQADV 5HG8 ARG A 858 UNP P00533 LEU 858 ENGINEERED MUTATION SEQADV 5HG8 ARG A 948 UNP P00533 VAL 948 ENGINEERED MUTATION SEQRES 1 A 329 GLY SER GLY GLU ALA PRO ASN GLN ALA LEU LEU ARG ILE SEQRES 2 A 329 LEU LYS GLU THR GLU PHE LYS LYS ILE LYS VAL LEU GLY SEQRES 3 A 329 SER GLY ALA PHE GLY THR VAL TYR LYS GLY LEU TRP ILE SEQRES 4 A 329 PRO GLU GLY GLU LYS VAL LYS ILE PRO VAL ALA ILE LYS SEQRES 5 A 329 GLU LEU ARG GLU ALA THR SER PRO LYS ALA ASN LYS GLU SEQRES 6 A 329 ILE LEU ASP GLU ALA TYR VAL MET ALA SER VAL ASP ASN SEQRES 7 A 329 PRO HIS VAL CYS ARG LEU LEU GLY ILE CYS LEU THR SER SEQRES 8 A 329 THR VAL GLN LEU ILE MET GLN LEU MET PRO PHE GLY CYS SEQRES 9 A 329 LEU LEU ASP TYR VAL ARG GLU HIS LYS ASP ASN ILE GLY SEQRES 10 A 329 SER GLN TYR LEU LEU ASN TRP CYS VAL GLN ILE ALA LYS SEQRES 11 A 329 GLY MET ASN TYR LEU GLU ASP ARG ARG LEU VAL HIS ARG SEQRES 12 A 329 ASP LEU ALA ALA ARG ASN VAL LEU VAL LYS THR PRO GLN SEQRES 13 A 329 HIS VAL LYS ILE THR ASP PHE GLY ARG ALA LYS LEU LEU SEQRES 14 A 329 GLY ALA GLU GLU LYS GLU TYR HIS ALA GLU GLY GLY LYS SEQRES 15 A 329 VAL PRO ILE LYS TRP MET ALA LEU GLU SER ILE LEU HIS SEQRES 16 A 329 ARG ILE TYR THR HIS GLN SER ASP VAL TRP SER TYR GLY SEQRES 17 A 329 VAL THR VAL TRP GLU LEU MET THR PHE GLY SER LYS PRO SEQRES 18 A 329 TYR ASP GLY ILE PRO ALA SER GLU ILE SER SER ILE LEU SEQRES 19 A 329 GLU LYS GLY GLU ARG LEU PRO GLN PRO PRO ILE CYS THR SEQRES 20 A 329 ILE ASP VAL TYR MET ILE MET ARG LYS CYS TRP MET ILE SEQRES 21 A 329 ASP ALA ASP SER ARG PRO LYS PHE ARG GLU LEU ILE ILE SEQRES 22 A 329 GLU PHE SER LYS MET ALA ARG ASP PRO GLN ARG TYR LEU SEQRES 23 A 329 VAL ILE GLN GLY ASP GLU ARG MET HIS LEU PRO SER PRO SEQRES 24 A 329 THR ASP SER ASN PHE TYR ARG ALA LEU MET ASP GLU GLU SEQRES 25 A 329 ASP MET ASP ASP VAL VAL ASP ALA ASP GLU TYR LEU ILE SEQRES 26 A 329 PRO GLN GLN GLY HET 634 A9001 28 HET SO4 A9002 5 HET SO4 A9003 5 HET GOL A9004 6 HETNAM 634 N-[3-({2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]-7H- HETNAM 2 634 PYRROLO[2,3-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROPANAMIDE HETNAM SO4 SULFATE ION HETNAM GOL GLYCEROL HETSYN 634 BOUND FORM OF N-[3-({2-[(1-METHYL-1H-PYRAZOL-4-YL) HETSYN 2 634 AMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL}OXY) HETSYN 3 634 PHENYL]PROP-2-ENAMIDE HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 2 634 C19 H19 N7 O2 FORMUL 3 SO4 2(O4 S 2-) FORMUL 5 GOL C3 H8 O3 FORMUL 6 HOH *209(H2 O) HELIX 1 AA1 LYS A 708 THR A 710 5 3 HELIX 2 AA2 ALA A 755 SER A 768 1 14 HELIX 3 AA3 CYS A 797 LYS A 806 1 10 HELIX 4 AA4 ASP A 807 ILE A 809 5 3 HELIX 5 AA5 GLY A 810 ARG A 831 1 22 HELIX 6 AA6 ALA A 839 ARG A 841 5 3 HELIX 7 AA7 PRO A 877 MET A 881 5 5 HELIX 8 AA8 ALA A 882 ARG A 889 1 8 HELIX 9 AA9 THR A 892 THR A 909 1 18 HELIX 10 AB1 PRO A 919 SER A 921 5 3 HELIX 11 AB2 GLU A 922 GLY A 930 1 9 HELIX 12 AB3 THR A 940 CYS A 950 1 11 HELIX 13 AB4 ASP A 954 ARG A 958 5 5 HELIX 14 AB5 LYS A 960 ARG A 973 1 14 HELIX 15 AB6 ASP A 974 LEU A 979 1 6 HELIX 16 AB7 GLY A 983 MET A 987 5 5 SHEET 1 AA1 6 ARG A 705 ILE A 706 0 SHEET 2 AA1 6 LEU A 777 LEU A 782 1 O ILE A 780 N ARG A 705 SHEET 3 AA1 6 VAL A 786 GLN A 791 -1 O ILE A 789 N GLY A 779 SHEET 4 AA1 6 ILE A 740 LEU A 747 -1 N ALA A 743 O MET A 790 SHEET 5 AA1 6 GLY A 724 TRP A 731 -1 N TYR A 727 O ILE A 744 SHEET 6 AA1 6 PHE A 712 GLY A 721 -1 N LEU A 718 O VAL A 726 SHEET 1 AA2 2 LEU A 833 VAL A 834 0 SHEET 2 AA2 2 LYS A 860 LEU A 861 -1 O LYS A 860 N VAL A 834 SHEET 1 AA3 2 VAL A 843 THR A 847 0 SHEET 2 AA3 2 HIS A 850 ILE A 853 -1 O LYS A 852 N LEU A 844 SHEET 1 AA4 2 TYR A 869 HIS A 870 0 SHEET 2 AA4 2 ILE A 890 TYR A 891 -1 O TYR A 891 N TYR A 869 LINK SG CYS A 797 C21 634 A9001 1555 1555 1.80 SITE 1 AC1 12 LEU A 718 ALA A 743 GLN A 791 MET A 793 SITE 2 AC1 12 PRO A 794 GLY A 796 CYS A 797 ARG A 841 SITE 3 AC1 12 LEU A 844 TYR A 998 HOH A9155 HOH A9265 SITE 1 AC2 5 ARG A 836 TYR A 869 ALA A 871 GLU A 872 SITE 2 AC2 5 HOH A9149 SITE 1 AC3 3 ARG A 803 ALA A 864 LYS A 913 SITE 1 AC4 9 GLU A 709 THR A 940 ILE A 941 ASP A 942 SITE 2 AC4 9 ARG A 977 TYR A 978 HOH A9117 HOH A9142 SITE 3 AC4 9 HOH A9172 CRYST1 39.932 69.730 110.610 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.025043 0.000000 0.000000 0.00000 SCALE2 0.000000 0.014341 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009041 0.00000